If you've been diagnosed with nsclc then biomarker testing is a subject about which you should know. The links below come from our 2022 targeted therapies forum.

Advantages of next generation sequencing in nsclc

Liquid biopsies in nscl

Biomarker testing for nsclc: The importance and the disparities

Who should receive next generation sequencing (NGS)?

The webinar has ended but you can watch this recording on-demand Here.

Our Targeted Therapies Forum was Saturday 7/16/2022. The forum was/is packed full of excellent, understandable, and useful information from our faculty of lung cancer specialists and Terri Conneran Founder of KRAS Kickers, lung cancer survivor, and patient advocate. Terri added a very important dimension to the day (she's one of us, a layperson who has a most personal stake in cancer treatment and patient advocacy).

You can watch it on-demand. NOTE: you need to scroll PAST, "Play Welcome Video" and "Test Your Connection"

down to the videos in orange boxes at "Morning Session", "Breakout Sessions", and "Afternoon Session" Here is the Agenda and Faculty Bios

In order to help prepare as many people as possible to be educated members of their own cancer care team, Grace is having its annual Targeted Therapies Forum live...online. In English on July 16, 2022, and in Spanish on July 30, 2022. Top oncologists in their field will meet online to discuss present standards of care and clinical trials. There will be large and small group discussions and Q and A.  Check in regularly as we get the schedule set. 

Just in case you've missed or misplaced our 2021 Targeted Therapies Forum check out Grace's refreshed Front Page links and links to the new faculty video series on clinical trials.

2021 EN VIVO ONLINE

Foro Español de Pacientes de Terapias Dirigidas
para pacientes y cuidadores que viven con cáncer de pulmón 22 de julio de 2021 6:30 - 8:00 PM hora del este

¡Regístrate ahora!

Únase a nosotros para este esperado evento anual transmitido en
vivo, que presenta a los mejores oncólogos en su campo
presentando la información más actual y emergente en terapias
dirigidas y respondiendo preguntas de los pacientes en tiempo real, en español.

¡Regístrate ahora!

La información más reciente sobre nuestro foro de terapias dirigidas, incluido el registro, la
agenda, y las biografías de los profesores, está disponible en www.cancergrace.org. Si tiene alguna pregunta sobre el registro para este evento, envíenos un correo electrónico a
info@cancerGRACE.org. Este evento virtual se realizará EN VIVO ONLINE
Para obtener más detalles, consulte la agenda completa y la
información de la facultad para obtener más información.

2021 Targeted Therapies Patient Forum  

To be held ONLINE July 17, 2021, 10:00 AM Eastern

Hope to see you there...LIVE...online.  :)

The Targeted Therapies Patient Forum from CancerGrace.org is finally here and FREE to anyone.  Originally scheduled for earlier this year our forum is now going to be held live online this Saturday, September 12, 2020.  

There’s no better way to get the most up to date information about research and real-life clinical practices than joining a group of professionals, patients, and caregivers for a day of lectures, panel discussions, and question and answer sessions.  

You’ve heard the saying 2 heads are better than one?  That goes doubly when you get a group of lung cancer specialists and researchers together.  I’ve been a member of Grace for over 10 years and have learned so many invaluable lessons from these types of group discussions.  This includes a variety of perspectives and detail only group discussions provide.  You’ll have ample opportunity to ask questions.  If you don’t already know, I think you’ll be heartened to see the genuine excitement from our faculty about new treatments and educating us so we can be players in the decision-making process. 

If you or someone you care about has NSCLC with a targetable mutation you won’t want to miss this forum.  

Here is the Agenda for Saturday, Faculty information, and Register here...See you there!  

Looks like the search function is up on the main pages and forum specific. Nice!

March 26, 2018 at 10:40 pm #1294138

bfarz
Hi, 64 Y/O female, asian, dx 12/2011 Stage 4 Adneo del 19 egfr+, Tarceva for almost 5 years, no progression, then small progression, Almita/Carbo 4 cycles as hold over, tissue biopsy T790M + , Lepidic predominant Adeno, Started Tagrisso 12/2016.
Ct scan today showed 1mm increase in size of a 3 mm nodule. Also a 3mm lesion is a bit more dense looking but unchanged in size. All other nodules and lesions remain unchanged.
Is this considered progression ? Does the RECIST criteria for progression apply to a small lesion like this?
Do we have to increase the frequency of the CT scans?

March 27, 2018 at 6:25 am #1294140
JimC Forum Moderator
JimC Forum Moderator
Hi bfarz,

Although a 1 mm change in a 3 mm nodule appears to be significant in terms of percentage increase, a change of 1 mm in any size nodule is not a clear indication of growth. Many factors related not to growth but to the scanning process can make an unchanged nodule appear to be a millimeter larger, such as the way the images “cut”, the use of a different CT machine and slight changes in the angle of the images. Most oncologists would not consider this clear evidence of progression and it would not impact their management of the cancer.

You didn’t state your current scan interval, but unless it’s quite long (a year or more), then your doctor will probably not see a need to shorten the interval. But that’s a matter of personal preference that varies from one oncologist to another, and given the stable results from the latest scan, there isn’t a strictly defined standard interval.

JimC
Forum moderator